Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings...

Descripción completa

Detalles Bibliográficos
Autores: Maurel, Marine, Howard, Jennifer, Kissling, Esther, Pozo Sanchez, Francisco, Pérez-Gimeno, Gloria, Buda, Silke, Sève, Noémie, McKenna, Adele, Meijer, Adam, Rodrigues, Ana Paula, Martínez-Baz, Iván, Mlinarić, Ivan, Latorre-Margalef, Neus, Túri, Gergő, Lazar, Mihaela, Mazagatos, Clara, Echeverria, Aitziber, Abela, Stephen, Bourgeois, Marc, Machado, Ausenda, Dürrwald, Ralf, Petrović, Goranka, Oroszi, Beatrix, Jancoriene, Ligita, Marin, Alexandru, Husa, Petr, Duffy, Róisín, Dijkstra, Frederika, Gallardo García, Virtudes, Goerlitz, Luise, Enouf, Vincent, Bennett, Charlene, Hooiveld, Mariëtte, Guiomar, Raquel, Trobajo-Sanmartín, Camino, Višekruna Vučina, Vesna, Samuelsson Hagey, Tove, Lameiras Azevedo, Ana Sofía, Castilla, Jesús, Xuereb, Gerd, Delaere, Bénédicte, Gomez, Verónica, Tolksdorf, Kristin, Bacci, Sabrina, Nicolay, Nathalie, Kaczmarek, Marlena, Rose, Angela Mc, European IVE group
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19055
Acceso en línea:http://hdl.handle.net/20.500.12105/19055
Access Level:acceso abierto
Palabra clave:Influenza Vaccines
Influenza, Human
Influenza A Virus, H1N1 Subtype
Humans
Influenza B virus
Influenza A Virus, H3N2 Subtype
Vaccination
Case-Control Studies
Seasons
Hospitals
Primary Health Care
Descripción
Sumario:Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

Similares en LA Referencia